These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35970690)

  • 1. Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.
    Birabaharan M; Martin TCS
    Am J Emerg Med; 2022 Nov; 61():235.e5-235.e6. PubMed ID: 35970690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
    Lai CC; Hsueh PR
    J Med Virol; 2023 Feb; 95(2):e28430. PubMed ID: 36571273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.
    Qi T; Jin Y; Wang H; Liao Y; Liu T; Mao E; Li F; Li Y; Fan X; Ling Y
    J Med Virol; 2023 Feb; 95(2):e28497. PubMed ID: 36651302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.
    Ranganath N; O'Horo JC; Challener DW; Tulledge-Scheitel SM; Pike ML; O'Brien M; Razonable RR; Shah A
    Clin Infect Dis; 2023 Feb; 76(3):e537-e539. PubMed ID: 35698452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nirmatrelvir-Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation.
    Lin CY; Cassidy AG; Li L; Prahl MK; Golan Y; Gaw SL
    Obstet Gynecol; 2023 May; 141(5):957-960. PubMed ID: 36928334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
    Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
    Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
    Dawood AA
    Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.
    Carlin AF; Clark AE; Chaillon A; Garretson AF; Bray W; Porrachia M; Santos AT; Rana TM; Smith DM
    Clin Infect Dis; 2023 Feb; 76(3):e530-e532. PubMed ID: 35723411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the use of Paxlovid in clinical practice.
    McCarthy MW
    Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir.
    Dai EY; Lee KA; Nathanson AB; Leonelli AT; Petros BA; Brock-Fisher T; Dobbins ST; MacInnis BL; Capone A; Littlehale N; Boucau J; Marino C; Barczak AK; Sabeti PC; Springer M; Stephenson KE
    medRxiv; 2022 Aug; ():. PubMed ID: 35982651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis.
    Amani B; Amani B
    J Med Virol; 2023 Feb; 95(2):e28441. PubMed ID: 36576379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.